Campbell Newman Asset Management Inc. Sells 10,481 Shares of AbbVie Inc. $ABBV

Key Points

• Campbell Newman Asset Management cut its AbbVie stake by 6.3%, selling 10,481 shares and retaining 154,908 shares valued at approximately $39.0 million. AbbVie represents 2.9% of the fund’s portfolio, while institutional investors collectively own 70.23% of the company.
• AbbVie exceeded quarterly expectations, reporting $3.65 in EPS versus a $3.61 consensus estimate and $16.99 billion in revenue, up 10.2% year over year. The company issued third-quarter 2026 EPS guidance of $3.84–$3.88.
• The stock recently traded at $249.20, and AbbVie paid a quarterly dividend of $1.73 per share, equating to a 2.8% annualized yield. Analysts maintain a “Moderate Buy” consensus with a $275.50 average price target, supported by neuroscience and post-Humira growth prospects but tempered by valuation and pipeline risks.

Campbell Newman Asset Management Inc. reduced its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 6.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 154,908 shares of the company's stock after selling 10,481 shares during the period. AbbVie comprises 2.9% of Campbell Newman Asset Management Inc.'s holdings, making the stock its 15th largest position. Campbell Newman Asset Management Inc.'s holdings in AbbVie were worth $38,981,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Litman Gregory Wealth Management LLC bought a new stake in AbbVie in the fourth quarter valued at approximately $28,000. Imprint Wealth LLC lifted its position in shares of AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company's stock valued at $29,000 after buying an additional 45 shares during the last quarter. Legacy Wealth Managment LLC ID boosted its stake in shares of AbbVie by 115.9% during the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company's stock worth $31,000 after acquiring an additional 73 shares during the period. IFC & Insurance Marketing Inc. bought a new position in shares of AbbVie during the 4th quarter worth approximately $31,000. Finally, WestEnd Advisors LLC increased its holdings in shares of AbbVie by 160.4% during the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company's stock worth $32,000 after acquiring an additional 85 shares during the last quarter. Institutional investors own 70.23% of the company's stock.

AbbVie Trading Down 0.6%

AbbVie stock opened at $249.20 on Friday. The company has a market capitalization of $440.29 billion, a price-to-earnings ratio of 70.40, a PEG ratio of 0.83 and a beta of 0.30. AbbVie Inc. has a 12 month low of $190.75 and a 12 month high of $267.47. The stock's 50 day moving average is $244.94 and its 200-day moving average is $226.12.

AbbVie (NYSE:ABBV - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analysts' expectations of $16.80 billion. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm's revenue for the quarter was up 10.2% compared to the same quarter last year. During the same period last year, the firm posted $2.97 EPS. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, equities research analysts predict that AbbVie Inc. will post 14.07 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 2.8%. AbbVie's dividend payout ratio (DPR) is presently 195.48%.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Neuroscience growth is gaining momentum: AbbVie’s neuroscience franchise delivered strong first-half growth, with Parkinson’s treatment Vyalev accelerating. Potential approval and commercialization of tavapadon could provide another growth driver in the second half of 2026. Can ABBV's Neuroscience Drugs Drive Growth in the Second Half of 2026?
• Positive Sentiment: Post-Humira diversification remains a key bullish theme: Analysts and investors point to resilient revenue growth from AbbVie’s next-generation immunology and aesthetics portfolio. Wolfe Research upgraded AbbVie on pipeline strength and valuation, while BNP Paribas Exane also expects the stock to rise. Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Positive Sentiment: Recent operating performance supports the growth case: AbbVie’s reported first-quarter 2026 revenue increased 12.4% year over year, while adjusted EPS exceeded internal expectations despite an acquired research-and-development charge. Could AbbVie Inc. Post-Humira Transformation Drive the Next Phase of Growth?
• Neutral Sentiment: Pipeline updates add potential but remain clinical-stage catalysts: AbbVie is expanding Alzheimer’s research with ABBV-1758 and studying Rinvoq against Humira in rheumatoid arthritis, while real-world China data for upadacitinib in atopic dermatitis could help reinforce Rinvoq’s commercial position. AbbVie Steps Deeper Into Alzheimer’s
• Negative Sentiment: Risks include valuation and pipeline uncertainty: A comparison with Bristol-Myers Squibb highlighted that AbbVie trades at a considerably richer valuation. Separately, the partners clarified a setback in the Phase 3 epcoritamab lymphoma study, and Erste Group Bank lowered its AbbVie earnings estimates—both potential sources of caution. Could AbbVie Win as Genmab Faces a New Regulatory Test for Epcoritamab?

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ABBV shares. Wells Fargo & Company increased their price target on AbbVie from $260.00 to $295.00 and gave the company an "overweight" rating in a research note on Friday, July 10th. UBS Group lifted their price objective on shares of AbbVie from $230.00 to $260.00 and gave the stock a "neutral" rating in a research report on Monday, July 13th. Canaccord Genuity Group upped their price objective on shares of AbbVie from $282.00 to $290.00 and gave the company a "buy" rating in a report on Monday, August 3rd. DZ Bank raised shares of AbbVie from a "hold" rating to a "strong-buy" rating in a research report on Thursday, April 30th. Finally, Cantor Fitzgerald increased their price objective on shares of AbbVie from $265.00 to $285.00 and gave the company an "overweight" rating in a research report on Monday, August 3rd. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie has a consensus rating of "Moderate Buy" and a consensus price target of $275.50.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source